文献速递肝病

「正常」肌酐水平可预测肝硬化门诊患者的持续性肾损伤和等待名单死亡率

"Normal" Creatinine Levels Predict Persistent Kidney Injury and Waitlist Mortality in Outpatients With Cirrhosis.
PubMed 文献 · Hepatology · 2018-07-10

该单中心研究分析了385例等待肝移植的肝硬化门诊患者,按基线血清肌酐(bCr)分为≤0.70、0.70-0.97和≥0.97 mg/dL三组。中位随访16个月,37%发生至少一次急性肾损伤(AKI),且随bCr组升高而增加(24%对37%对48%,P=0.001)。多变量Cox回归显示bCr(HR 2.96)和ΔCr(HR 2.05)是持续性肾损伤的独立相关因素(P<0.001)。死亡/除名风险随bCr组升高而增加(14%对19%对28%,P=0.03),竞争风险分析显示bCr每增加1 mg/dL,死亡/除名风险独立增加62%。结论认为AKI在肝硬化门诊患者中常见,即使「临床正常」的bCr水平也显著影响持续性肾损伤和等待名单死亡率,支持需要更低的临床阈值来启动肾功能监测和实施肾脏保护策略。

要点

  • 肝硬化门诊患者中37%发生至少一次AKI,且发生率随基线肌酐升高而增加。
  • 基线肌酐(HR 2.96)和肌酐变化值(HR 2.05)是持续性肾损伤的独立相关因素。
  • 基线肌酐每增加1 mg/dL,死亡/除名风险独立增加62%。

核心结论

  • AKI在肝硬化门诊患者中常见,即使「临床正常」的基线肌酐水平也显著影响持续性肾损伤和等待名单死亡率,支持需要更低的临床阈值来启动肾功能监测和实施肾脏保护策略。

研究设计与样本

  • 单中心分析385例等待肝移植的肝硬化成人门诊患者,排除严重肝性脑病、肝细胞癌或接受血液透析者。
  • 基线血清肌酐(bCr)定义为记录的最低值,峰值肌酐为最高值,ΔCr为峰值减基线。
  • AKI定义为血清肌酐较bCr升高≥0.3 mg/dL,持续性肾损伤定义为每次后续临床评估时血清肌酐较bCr升高≥0.3 mg/dL。

主要发现

  • bCr≤0.70、0.70-0.97和≥0.97 mg/dL的患者分别占28%、38%和34%。
  • 中位随访16个月(范围8-28个月),143例(37%)发生至少一次AKI,随bCr组升高而增加(24%对37%对48%,P=0.001)。
  • 143例发生AKI的患者中,13%发展为持续性肾损伤。
  • 多变量Cox回归显示bCr(HR 2.96)和ΔCr(HR 2.05)是持续性肾损伤的独立相关因素(P<0.001)。
  • 死亡/除名可能性随bCr组升高而增加(14%对19%对28%,P=0.03);竞争风险分析显示bCr每增加1 mg/dL,死亡/除名风险独立增加62%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute kidney injury (AKI) is a critical determinant of outcomes in hospitalized patients with cirrhosis, but little is known of the impact of AKI in the outpatient setting. We analyzed 385 adult outpatients with cirrhosis listed for liver transplant at a single center; excluded were those with severe hepatic encephalopathy, with hepatocellular carcinoma, or on hemodialysis. Baseline serum creatinine (bCr) was defined as the lowest value recorded, peak Cr as the highest value, ΔCr as peak Cr minus bCr, AKI as a rise in serum Cr (sCr) by ≥0.3 mg/dL from bCr, persistent kidney injury as elevation of sCR by ≥0.3 mg/dL from bCr on each subsequent clinical assessment. Among 385 outpatients with cirrhosis, bCr was ≤0.70, 0.70-0.97, and ≥0.97 mg/dL in 28%, 38%, and 34%, respectively. At a median follow-up of 16 (range 8-28) months, 143 (37%) had one or more AKI episode, which increased significantly by bCr group (24% versus 37% versus 48%, P = 0.001). Of these 143 with AKI, 13% developed persistent kidney injury. A multivariable Cox regression analysis highlighted that bCr (hazard ratio [HR], 2.96) and ΔCr (HR, 2.05) were the only factors independently associated with the development of persistent kidney injury (P < 0.001). The likelihood of death/delisting increased by bCr group (14% versus 19% versus 28%, P = 0.03). A competing risk analysis demonstrated that each 1 mg/dL increase in bCr was independently associated with a 62% higher risk of death/delisting when accounting for transplantation and adjusting for confounders. Conclusion: AKI is not only common in outpatients with cirrhosis but even "clinically normal" bCr levels significantly impact the risk of persistent kidney injury and waitlist mortality, supporting the need for a lower clinical threshold to initiate monitoring of renal function and implementation of kidney-protective strategies.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Cullaro G, Park M, Lai JC, et al. "Normal" Creatinine Levels Predict Persistent Kidney Injury and Waitlist Mortality in Outpatients With Cirrhosis. Hepatology. 2018. PMID: 29698588. doi:10.1002/hep.30058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。